APA (7th ed.) Citation

F, B., G, D., F, N., M, C., & R, N. (2026). Efficacy of rituximab treatment in a post-COVID-19 vaccine myositis overlapping to systemic sclerosis: A histological follow-up. Clinical and experimental rheumatology, 44(2), 415. https://doi.org/10.55563/clinexprheumatol/8xtlep

Chicago Style (17th ed.) Citation

F, Bandinelli, Dallagiacoma G, Nozzoli F, Capassoni M, and Nassini R. "Efficacy of Rituximab Treatment in a Post-COVID-19 Vaccine Myositis Overlapping to Systemic Sclerosis: A Histological Follow-up." Clinical and Experimental Rheumatology 44, no. 2 (2026): 415. https://doi.org/10.55563/clinexprheumatol/8xtlep.

MLA (9th ed.) Citation

F, Bandinelli, et al. "Efficacy of Rituximab Treatment in a Post-COVID-19 Vaccine Myositis Overlapping to Systemic Sclerosis: A Histological Follow-up." Clinical and Experimental Rheumatology, vol. 44, no. 2, 2026, p. 415, https://doi.org/10.55563/clinexprheumatol/8xtlep.